Tag: delta opioid receptor agonist
PharmNovo reports broader therapeutic potential for PN6047
PharmNovo AB has announces new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the...
PharmNovo completes drug product manufacturing for Phase IIa study of PN6047
PharmNovo is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain, an area with significant unmet medical need. The...
PharmNovo awarded blended funding of €17.5M from EIC
PharmNovo, a Swedish clinical-stage pharmaceutical company, has been awarded €17.5 M in blended funding from the European Innovation Council (EIC) Accelerator under the Horizon...